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The studies by Michael Sharpe and colleagues1 in 
The Lancet and by Jane Walker and colleagues2 in 
The Lancet Oncology show a rigorous approach to the 
implementation and assessment of a complex intervention 
to alleviate depression in people with cancer. This research 
is timely, since the risk of depression has been shown to be 
two-to-three-times higher in patients with cancer than 
in the general population,3 and could contribute to the 
poorer quality of life4 and increased risk of suicide in such 
individuals.5 Neurobiological factors might play a part in the 
link between cancer and depression,6 but much evidence 
suggests that depression in this population represents a 
ﬁ nal common pathway of distress that results from the 
interaction of several diverse risk and vulnerability factors.7 
Substantial advances in the treatment of cancer have 
been made during the past few decades, but attention 
to the physical and psychological symptoms of this 
disease and its treatment has been given lower priority in 
clinical settings. To address this imbalance, professional 
bodies have mandated that routine distress screening 
be a standard of practice in cancer treatment settings.8 
Such screening needs to be linked to an eﬀ ective 
intervention programme for it to be clinically eﬀ ective, 
although only sparse evidence has shown the beneﬁ t 
of such interventions in patients with cancer.9 In other 
medical populations, positive outcomes in the treatment 
of depression have been shown to be achievable by a 
collaborative care approach that links care managers or 
nurses with primary care physicians and psychiatrists 
to provide and adjust psychological or pharmacological 
treatment, to monitor outcomes, and to ensure treatment 
compliance.10
Sharpe and colleagues have developed a collaborative 
care intervention for depression, which is referred 
to as depression care for people with cancer. This is a 
complex intervention involving both antidepressant 
medication and psychological treatment that makes 
available for each patient contact with, or input from, 
a nursing case manager trained in problem-solving 
therapy and behavioural activation, a primary care 
physician, a psychiatrist, and liaison with the patient’s 
oncologist. The SMaRT Oncology-2 multicentre phase 
3 trial of depression care for people with cancer is a 
major study in which 500 patients from three cancer 
centres in Scotland, UK, all with an expected survival of 
at least 12 months and a diagnosis of major depression, 
were randomly assigned to depression care for 
people with cancer or to usual care. 90% of the study 
population were women, and a participation rate of 
47% was achieved among eligible patients. The primary 
outcome was treatment response at 24 weeks, deﬁ ned 
by a 50% or greater reduction in depression severity 
on a self-reported measure (the Symptom Checklist 
Depression Scale [SCL-20]), although patients were 
followed for up to 48 weeks. Several other secondary 
and tertiary outcomes were also assessed, including 
depression, anxiety, physical distress, functional 
capacity, and quality of life.
The treatment eﬀ ect in SMaRT Oncology-2 is 
impressive, with 62% (143 of 231) of the depression 
care for people with cancer group having a response at 
24 weeks, compared with only 17% (40 of 231) of those 
in the usual care group (adjusted odds ratio 8·5 [95% 
CI 5·5–13·4]). Statistically signiﬁ cant diﬀ erences were 
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decision makers about how they can act now to 
protect the lives of a future generation of women and 
children.
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also recorded between the two groups on all the 
secondary and tertiary outcomes. These beneﬁ ts, 
which persisted throughout the trial, are greater than 
those reported by this group in their 2008 eﬃ  cacy trial 
of this intervention.11 In the present study, patients 
in the depression care treatment group received up 
to ten sessions with a nurse and were more likely to 
receive an eﬀ ective dose of antidepressant medication 
than were those in the usual care group. Very few 
patients in the usual care group received counselling 
or a formal psychological intervention. The depression 
care intervention in this study was estimated to cost an 
additional £613 per patient, based on the cost of the 
treatment sessions, telephone contacts, and treatment 
supervision, although implementation in other cancer 
settings would incur further setup costs. How such a 
system of care could be implemented or modiﬁ ed to be 
feasible in lower resource settings that do not have ready 
access to primary care physicians, nurses, psychiatrists, 
and oncologists is a challenge that is yet to be addressed. 
The depression care for people with cancer research 
group has simultaneously published a randomised 
controlled eﬃ  cacy trial comparing this intervention to 
usual care for patients with lung cancer with an expected 
survival of at least 3 months. In this SMaRT Oncology-3 
trial,2 Walker and colleagues recruited 142 participants 
(43% of those eligible), all of whom had major depression. 
The primary outcome for this trial was depression severity 
(measured on the SCL-20) averaged over the time in the 
trial, which was chosen in part because of the potential for 
missing data caused by the anticipated physical decline 
and death of these patients. In fact, 30% (43 of 142) of the 
participants died during the course of the trial.
Those in the depression care for people with lung 
cancer group received a median of eight treatment 
sessions with the nurse, were more likely than were 
those in the usual care group to receive an eﬀ ective 
dose of an antidepressant medication, and half of them 
had contact with a psychiatrist. No patient in either the 
treatment or control group received formal psychological 
treatment from non-depression care for people with 
lung cancer providers. Although not as dramatic as the 
results of SMaRT Oncology-2, a statistically signiﬁ cant 
improvement in depression severity was recorded in 
the depression care for people with lung cancer group 
(mean score on the SCL-20 1·24 [SD 0·64]) compared 
with the usual care group (mean score 1·61 [SD 0·58]; 
diﬀ erence –0·38 (95% CI –0·58 to –0·18). Improvements 
in some of the secondary outcomes were also recorded 
in the depression care for people with lung cancer group 
compared with the usual care group. 
These two well-designed studies show that a 
multicomponent intervention can achieve a sustained 
improvement in the symptoms of depression in patients 
with cancer. This ﬁ nding is a testament to the rigour of 
the studies and the nature of the treatment framework 
in which they took place. The individual components 
of the intervention are not themselves novel, but the 
beneﬁ t of their delivery in an integrated system of this 
type has not previously been shown in patients with 
cancer. The treatment received by the control group 
in both studies shows that these interventions are not 
routinely and consistently applied in the usual care of 
patients with cancer, even when they are available.
What cannot be established from the SMaRT Oncology 
studies is which components of this complex intervention 
are its most active ingredients.12 It is not possible in these 
studies to disentangle the eﬀ ects of the antidepressant 
medication, the non-speciﬁ c support and close follow-up, 
the problem-solving and behavioural activation delivered 
by the nurses, or their supervisory support. Phased 
research12 is needed to establish the eﬀ ect of speciﬁ c 
components, and further studies are indicated to ascertain 
the beneﬁ t of minimal interventions or those tailored to 
address problems related to the cancer type or to the stage 
of disease.13 However, these two new research studies of 
a collaborative care intervention for depression in cancer 
patients represent a signiﬁ cant advance in knowledge 
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The 10-year survival for patients with metastatic 
melanoma is less than 10%.1 After decades of 
failed attempts to improve treatment outcomes in 
patients with this disease,2 the recent successes with 
ipilimumab and the inhibitors of BRAF and MEK 
(vemurafenib, dabrafenib, and trametinib) have 
ushered in a new era in systemic therapy.3–7 These 
breakthroughs have not only provided more treatment 
options for patients with melanoma, but have also 
spurred the investigation of a new generation of drugs 
for cancer therapy. In The Lancet, Caroline Robert and 
colleagues8 report the results of programmed-death-
receptor-1 (PD-1) blockade with pembrolizumab 
(MK-3475) in patients with melanoma previously 
treated with an anti-cytotoxic T-lymphocyte-
associated-antigen-4 (CTLA-4) antibody ipilimumab; 
these ﬁ ndings are another important advance in the 
rapidly evolving landscape of cancer immunotherapy.
Robert and colleagues report on a randomised 
open-label trial expansion cohort of the phase 1 
KEYNOTE-001 trial, comparing the eﬃ  cacy and safety 
of two doses of pembrolizumab (2 mg/kg and 
10 mg/kg administered intravenously every 3 weeks) 
in 173 patients with metastatic melanoma who had 
previously been treated with at least two doses of 
ipilimumab and had progressed within 24 weeks after 
the last dose of ipilimumab. Patients with a history 
of severe immune-related adverse events requiring 
prolonged (>12 weeks) treatment with steroids 
were not included. 64% of the study population 
had M1c disease and 39% had elevated lactate 
dehydrogenase concentrations. Treatment with both 
doses of pembrolizumab in this ipilimumab-treated 
population was associated with an objective response 
rate of 26%, the trial’s primary endpoint; estimated 
progression-free survival at 24 weeks was 45% in the 
2 mg/kg group and 37% in the 10 mg/kg group, and 
estimated 1-year overall survival was 58% and 63%, 
respectively. 88% of the responders were alive and 
progression free at the time of analysis, with at least 
6 months of follow-up. Treatment was tolerated 
well with drug-related grade 3 to 4 adverse events 
reported in only 12% of patients. Only 3% of patients 
discontinued treatment due to drug-related adverse 
Melanoma: immune checkpoint blockade story gets better
Published Online
July 15, 2014
http://dx.doi.org/10.1016/
S0140-6736(14)61140-5
See Articles page 1109 
and suggest that treatments for depression delivered 
within such a framework might be most likely to achieve 
a positive outcome.
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